Table 3 Baseline characteristics of patients in outcomes study
Patients previously treated with two treatment lines | Cetuximab group (n = 23) | BSC group (n = 35) | P values | |
|---|---|---|---|---|
Male | 60% | 65% | NS (p = 0.16) | |
Age, median (years) | 64 | 60 | p < 0.05 | |
PS | 0 | 26% | 6% | p < 0.05 |
1 | 17% | 11% | ||
2 | 9% | 3% | ||
3 | – | – | ||
4 | 4% | – | ||
Unknown | 43% | 80% | ||
Location | Colon | 48% | 54% | NS (p = 0.9) |
Rectum | 35% | 31% | ||
Rectosigmoid | 13% | 9% | ||
Unknown | 4% | 6% | ||
Charlson Indexa | 6 | 35% | 63% | NS (p = 0.1) |
7 | 35% | 17% | ||
8 | 17% | 11% | ||
9 | – | 6% | ||
10 | 9% | – | ||
Unknown | 4% | 3% | ||
Mean total treatment duration (days) | 398 | 264 | p < 0.05 | |
Mean treatment duration prior to BSC or cetuximab (days) | 268 | 264 | NS (p = 0.9) | |